14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
ZLAB vs HCM: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, HUTCHMED (China) Limited (HCM) is the stronger overall head-to-head candidate over Zai Lab Limited (ZLAB) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ZLAB carries a Unified Composite Score of 47.4/100 (HOLD) at $23.74 (N/M Forward P/E, -63.0% operating margin), whereas HCM carries 37.9/100 (SELL) at $14.69 (N/M Forward P/E, -6.3% operating margin).
Composite vs. Pillar Nuance: While ZLAB currently prints a higher short-term Unified Composite Score (47.4/100 HOLD vs. HCM 37.9/100 SELL), HCM captures the overall institutional head-to-head verdict (7–2 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-6.3% vs. -63.0% operating margin) and revenue trajectory (+0.2% vs. -6.8% YoY).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ZLAB vs HCM. Trailing 12-month operating profitability (ZLAB -63.0% vs HCM -6.3%) and valuation multiples (ZLAB N/M vs HCM N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Drug Manufacturers - Specialty & Generic value chain with $2.6B market capitalization and -6.3% operating margin.
OpEx & R&D Reinvestment19.6% of Rev ($108M)
90D Engineering Disclosures0 Published
Investor FAQ ZLAB vs HCM Key Questions & Quantitative Answers
As of Nov 16, 2026, HUTCHMED (China) Limited (HCM) is the stronger overall head-to-head candidate over Zai Lab Limited (ZLAB) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ZLAB carries a Unified Composite Score of 47.4/100 (HOLD) at $23.74 (N/M Forward P/E, -63.0% operating margin), whereas HCM carries 37.9/100 (SELL) at $14.69 (N/M Forward P/E, -6.3% operating margin). Composite vs. Pillar Nuance: While ZLAB currently prints a higher short-term Unified Composite Score (47.4/100 HOLD vs. HCM 37.9/100 SELL), HCM captures the overall institutional head-to-head verdict (7–2 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-6.3% vs. -63.0% operating margin) and revenue trajectory (+0.2% vs. -6.8% YoY).
HCM leads the Growth & Scale pillar: ZLAB posts -6.8% YoY revenue growth and +0.0% YoY earnings growth on $442M TTM revenue (0.6% gross margin, -63.0% operating margin), compared with HCM at +0.2% YoY revenue growth and -96.5% YoY earnings growth on $549M TTM revenue (13.3% gross margin, -6.3% operating margin). On trailing 12-month operating scale, ZLAB generates $442M in USD-normalized revenue versus $549M for HCM. In operating R&D and SG&A reinvestment, ZLAB deploys 63.6% of Rev ($281M) (0 90-day corporate R&D disclosures) versus 19.6% of Rev ($108M) (0 disclosures) for HCM.
HCM screens cheaper on headline valuation multiples. ZLAB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.8x EV/Revenue (-59.3% EBITDA margin), whereas HCM trades at N/M Forward P/E, 148.3x Trailing P/E, N/M PEG, and 4.7x EV/Revenue (-3.7% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ZLAB (-30.0% ROE) versus HCM (1.5% ROE) capital efficiency.
In options market volatility and institutional positioning, ZLAB carries 58.4% implied volatility (58th %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.19β · 78% Vol realized risk). By comparison, HCM carries 82.7% implied volatility (73rd %ile, Elevated (60th–80th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.61β · 45% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.